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http://dx.doi.org/10.1016/j.jmii.2012We report the case of using a long-term combination of meropenem and amikacin to treat
infective endocarditis caused by Enterobacter cloacae resistant to third- and fourth-
generation cephalosporins. Multi-drug resistant Gram-negative bacilli, such as the E. cloacae
in our study, may become possible pathogens of infective endocarditis. Our experience with
this case indicates that long-term use of a combination of b-lactam and aminoglycosides might
represent a suitable management option for future infective endocarditis cases due to non-
Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, Kingella spp. (HACEK group)
Gram-negative bacilli such as ours.
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Infective endocarditis (IE) is a serious infectious disease
that carries a high mortality rate.1,2 Long-term use of
antibiotics is required, and surgical intervention is also
necessary in many cases. Gram-positive cocci such as
Streptococcus spp. and Staphylococcus spp. are mainly
responsible for infective endocarditis. On the other hand,
there are few reported cases of IE due to Gram-negative
bacilli (GNB).3 In these rare GNB IE cases, groups of GNB
consisting of Haemophilus, Actinobacillus, Cardiobacterium,
Eikenella, and Kingella spp. (HACEK) are the predominant
cause.3 In contrast, Enterobacter spp., a non-HACEK GNB,
has been reported to be an extremely rare pathogen of IE.
In fact, 49 of all 2761 cases of IE were shown to be due to
non-HACEK GNB, and only two were due to Enterobacter
cloacae.4 Although rare, IE due to non-HACEK GNB including
E. cloacae is known to be highly severe.4
Multidrug-resistant GNB has become a major public
health threat. Beta-lactamase producing GNB is especially
important pathogens because of their resistance to antibi-
otics. The AmpC b-lactamase gene is naturally carried by
certain enterobacteriaceae such as Enterobacter spp.
Exposure to b-lactam can induce the expression of AmpC b-
lactamases in these species, with consequent resistance to
third-generation cephalosporin and mutations resulting in
persistent resistance.5 Extended spectrum b-lactamase
(ESBL) is also well known as a cause of multidrug-resistance
in GNB. Productions of ESBLs often can lead to resistance of
fourth-generation cephalosporins.5
We present the survival case of IE due to E. cloacae
resistant to third- and fourth-generation cephalosporins.
The treatment protocol followed in this case demonstrates
that a successful outcome is possible with long-term anti-
biotic medicines and without surgical intervention.
Case report
A 74-year-old Japanese man, suffering from a fever above
38C for 2 weeks, was admitted to a hospital. The patient
was previously diagnosed with liver cirrhosis (LC) due to
hepatitis B virus infection at the age of 70; however,
treatment was not sought at the time. Chest/abdominal
radiographies and an abdominal ultrasonography upon
admission revealed normal findings. Blood testing showed
a white blood cell (WBC) count of 11.7  109/L and a C-
reactive protein (CRP) level of 105 mg/L, yet there were no
other significant findings to reveal the focus of infection.
Intravenous ceftriaxone, 2 g every 24 hours, was adminis-
tered from the day of admission; however, the fever
continued to persist for 10 days and the patient was
transferred to our hospital for further examination.
Upon admission to our hospital, the patient’s tempera-
ture was 39.0C. A Grade IV/VI systolic heart murmur was
most evident at the cardiac apex. Petechiae were observed
in the skin of the lower legs and in palpebral conjunctivae.
Laboratory findings showed a WBC count of 8.3  109/L with
no shift to the left, a platelet count of 96  109/L, and
a CRP level of 82.1 mg/L. The serum albumin level was
21 g/L, total bilirubin was 7.1 mg/L and prothrombin time
was 19.6 seconds. Transthoracic and transesophagealechocardiography revealed moderate mitral regurgitation
and vegetation with 14  8 mm on the posterior leaflet of
the mitral valve. Brain magnetic resonance imaging showed
three embolic cerebral infarctions. Chest/abdominal
computed tomography showed 2  3 cm of splenic infarct
and ascites. Blood was collected three times after admis-
sion, and blood cultures were performed. Blood cultures
revealed E. cloacae in all three samples. All three cultures
were demonstrated to be the bacterium resistant to third-
and fourth-generation cephalosporins by the antimicrobial
susceptibility test. The antimicrobial susceptibility test also
showed that E. cloacae, in this case, was sensitive to ami-
noglycosides and carbapenems. The patient was diagnosed
with IE due to E. cloacae resistant to third- and fourth-
generation cephalosporins and ChildePugh class C LC.
A meropenem dose of 1.0 g IV every 8 hours and an
amikacin dose of 800 mg IV every 24 hours were adminis-
tered from the day of admission to our hospital. After
the initial administration of meropenem and amikacin, the
fever rapidly declined, and blood cultures collected on
the second day of the administration of antibiotics were
negative. WBC counts were decreased and CRP levels
declined gradually. Brain magnetic resonance imaging and
systematic computed tomography, and transthoracic and
transesophageal echocardiography were repeated every 4
weeks after admission to our hospital. Eight weeks after
treatment, the size of splenic infarction was reduced and
no other embolic infarction was observed and the vegeta-
tion on the mitral valve had disappeared. Administration of
meropenem and amikacin was terminated 12 weeks after
the initiation of treatment. At the time of writing, the
patient had been well for 6 months without relapse.Discussion
Some specialists recommend that cases of IE associated
with non-HACEK GNB should be managed by early surgery,
combined with long-term (>6 weeks) therapy consisting of
combinations of b-lactams and aminoglycosides, others
have reported that the mortality rate is identical in surgical
and nonsurgical cases as well as in patients treated with
dual- as opposed to single-antibiotics.4 Our patient was
managed with a long-term combination of antibiotics and
no surgical intervention. This protocol may represent
a suitable management option for future IE cases due to
non-HACEK GNB, although a large series of case studies is
needed to demonstrate generalizability. Indeed, recently,
Moon et al showed that surgical intervention was not
needed in the treatment of IE due to E. cloacae in their
case.6 This report indicates that management with antibi-
otics alone was suitable for IE cases caused by E. cloacae.
We used carbapenem for treatment. We believe that it may
be beneficial to use broad-spectrum b-lactams in the
empirical treatment of severe GNB infections, because
resistant strains of GNB, including b-lactamase-producing
GNB, are increasing in number.7
E. cloacae in this case was resistant to third- and fourth-
generation cephalosporins. E. cloacae have chromosome-
encoded AmpC b-lactamase genes, and can naturally
produce AmpC b-lactamase. In contrast, fourth-generation
cephalosporins are comparatively stable to AmpC b-
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option for the treatment of Enterobacter infections.5
Although the results from the disk diffusion test by the
Clinical and Laboratory Standards Institute we performed
showed that clavulanic acid did not affect the growth of
this strain (data not shown), the production of ESBLs in E.
cloacae in this case remains to be suspected, especially
because the double disk assay can be influenced by the
presence of AmpC b-lactamase.5,8
Regarding the duration of treatment, although there is
no evidence to suggest how long antibiotics should be used
in non-HACEK GNB IE, a longer duration of antibiotic
treatment would be ideal because, according to established
guidelines, GNB IE should be treated with antibiotics for
more than 4 weeks to cure and prevent relapse.3 Our
patient was managed without surgical treatment because
of the patient’s severe LC, although this choice was
controversial. It has been reported that severe liver
cirrhosis should not be treated with cardiac surgery, but, on
the other hand, some specialists suggested that cardiac
operations could be performed safely in patients with mild
and advanced liver cirrhosis, although postoperative
complications are common.9,10 A large series of case studies
are needed to reveal whether surgical treatment should be
administered under the same conditions as those in our
patient. Gut translocation of E. cloacae may have caused
bacteremia and finally IE in our patient; however we were
unable to identify its site of entry.11
In conclusion, we present a case of IE due to E. cloacae
resistant to third- and fourth-generation cephalosporins
successfully treated using a combination of meropenem and
amikacin for 12 weeks. Multi-drug resistant GNB, such as
the E. cloacae in our case, may become possible pathogens
of IE. We believe that a long-term combination of b-lactam
and aminoglycoside may represent a suitable management
option for future IE cases due to non-HACEK GNB.
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